Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz® ▼ (ixekizumab): Effekt hos tidigare användare av Secukinumab i psoriasisartrit

Behandlingsvar på ixekizumab hos patienter som hade ett otillräckligt svar på secukinumab har inte utvärderats i systemiska studier av Lilly.

Ixekizumab Clinical Trial Exclusion Criteria Regarding IL-17 Antagonists

Psoriatic Arthritis

Patients were excluded from SPIRIT-P1 and SPIRIT-P2 if they had received IL-17 targeted mAb therapy.1,2

Therapeutic Indication

Ixekizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.3

References

1. Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomized, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317-2327. http://dx.doi.org/10.1016/S0140-6736(17)31429-0

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

IL-17 = interleukin-17

Lilly = Eli Lilly and Company

mAb = monoclonal antibody

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M07 10


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss